CTLA4 and neoplasm: The use of immune checkpoint inhibitors, such as anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies, allows the reactivation of an adaptive anti-tumor immune reaction and opens the development and clinical validation of immunotherapy in thyroid cancer [45].